A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder

被引:14
作者
Komaram, Ravi Babu [1 ]
Nukala, Srikrishna [2 ]
Palla, Jayasree [3 ]
Nambaru, Lakshmana Rao [4 ]
Kasturi, Satyanarayana Murthy [1 ]
机构
[1] GSL Med Coll & Gen Hosp, Dept Pharmacol, Rajahmundry, Andhra Pradesh, India
[2] GSL Med Coll & Gen Hosp, Dept Psychiat, Rajahrnundry, Andhra Pradesh, India
[3] GSL Med Coll & Gen Hasp, Dept Community Med, Rajahmundry, Andhra Pradesh, India
[4] RIMS, Dept Community Med, Stat, Ongole, Andhra Pradesh, India
关键词
Antidepressants; Depression; Melatonergic receptors; 5-HT2C receptors;
D O I
10.7860/JCDR/2015/12371.6092
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Major depressive disorder (MDD) is a mental disorder characterized by episodes of depressed mood, loss of interest or pleasure, feeling of guilt or low self-esteem, loss of energy, altered sleep patterns and difficulty in concentration. Objective: This study was carried out to compare the efficacy and safety of Agomelatine with Escitalopram in the treatment of major depressive disorder. Design and Setting: This is a prospective study conducted at Outpatient Department of Psychiatry, GSL Medical College & General hospital, Rajahmundry, India. Materials and Methods: Patients with newly diagnosed major depressive disorder (DSM-IV-TR) with minimum score of 20 in Hamilton depression rating scale were randomly assigned Agomelatine (25-50 mg/day) or Escitalopram (10-20 mg/day) for a period of 8 weeks. The main efficacy outcome considered was the mean change of HAM-D17 score from baseline to end of therapy. Secondary outcome measures were Clinical Global Impressions-improvement (CGI) and severity (CGI-S) rating scales. Statistical Analysis: Student t-test was used for comparing the groups and chi-square test was used for assessing the qualitative variables. For all statistical analysis p<0.05 was considered statistically significant. Results: The drugs under study effectively reduced depressive symptoms at all the time points. The percentage of responders at 8weeks (last post baseline value) was 65.38% with Agomelatine and 57.40% with Escitalopram. The difference between the drugs was statistically not significant in all evaluations (p>0.05). The mean CGI-S and CGI-I scores were decreased in both the groups (p<0.05) and there was no statistically significant difference between the groups at any assessment during the study period. Both the treatment groups showed favourable safety profile. Conclusion: The study results supported that Agomelatine is therapeutically similar to Escitalopram in terms of antidepressant effect.
引用
收藏
页码:VC5 / VC8
页数:4
相关论文
共 24 条
[1]
American Psychiatric Association, 2022, DIAGN STAT MAN MENT, V5th, DOI [10.1176/APPI.BOOKS.9780890425787, 10.1176/appi.books.9780890425787, DOI 10.1176/APPI.BOOKS.9780890425787]
[2]
Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial [J].
Corruble, Emmanuelle ;
de Bodinat, Christian ;
Belaidi, Carole ;
Goodwin, Guy M. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (10) :2219-2234
[3]
The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice [J].
De Berardis, Domenico ;
Marini, Stefano ;
Fornaro, Michele ;
Srinivasan, Venkataramanujam ;
Iasevoli, Felice ;
Tomasetti, Carmine ;
Valchera, Alessandro ;
Perna, Giampaolo ;
Quera-Salva, Maria-Antonia ;
Martinotti, Giovanni ;
di Giannantonio, Massimo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06) :12458-12483
[4]
Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug? [J].
Fornaro, Michele ;
Bandini, Fabio ;
Cestari, Luca ;
Cordano, Christian ;
Ogliastro, Carla ;
Albano, Claudio ;
De Berardis, Domenico ;
Martino, Matteo ;
Escelsior, Andrea ;
Rocchi, Giulio ;
Fornaro, Pantaleo ;
De Pasquale, Concetta .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 :907-914
[5]
A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation [J].
Fornaro, Michele ;
Prestia, Davide ;
Colicchio, Salvatore ;
Perugi, Giulio .
CURRENT NEUROPHARMACOLOGY, 2010, 8 (03) :287-304
[6]
Golan David E., 2012, PRINCIPLES PHARM
[7]
Guy W., 1976, ECDEU ASSESSMENT MAN, P217
[8]
A RATING SCALE FOR DEPRESSION [J].
HAMILTON, M .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1960, 23 (01) :56-62
[9]
Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline [J].
Kasper, Siegfried ;
Hajak, Goeran ;
Wulff, Katharina ;
Hoogendijk, Witte J. G. ;
Luis Montejo, Angel ;
Smeraldi, Enrico ;
Rybakowski, Janusz K. ;
Quera-Salva, Maria-Antonia ;
Wirz-Justice, Anna M. ;
Picarel-Blanchot, Francoise ;
Bayle, Franck J. .
JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (02) :109-120
[10]
Lam RW, 2008, J PSYCHOPHARMACOL S, V22, P13